 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1661 News |  |
| «12...11121314151617181920212223» |
- |||| Inlyta (axitinib) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment open, Phase classification, HEOR, Real-world evidence, Real-world, Metastases: ADONIS: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (clinicaltrials.gov) - Nov 18, 2014
P4, N=750, Enrolling by invitation, Sponsor: Pfizer
Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- |||| Torisel (temsirolimus) / Pfizer
Trial primary completion date: RAY : Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (clinicaltrials.gov) - Nov 7, 2014
P3, N=280, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Trial primary completion date: Aug 2014 --> Feb 2015
- Torisel (temsirolimus) / Pfizer
Trial primary completion date: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - Nov 3, 2014
P2, N=40, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Aug 2014 --> Feb 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- || Torisel (temsirolimus) / Pfizer
Enrollment status, Phase classification: Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Oct 31, 2014
P4, N=120, Enrolling by invitation, Sponsor: Pfizer
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- || Torisel (temsirolimus) / Pfizer
Enrollment status, Phase classification: INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus (clinicaltrials.gov) - Oct 31, 2014
P4, N=100, Enrolling by invitation, Sponsor: Pfizer
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- sirolimus / Generic mfg.
Phase classification, Metastases: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer (clinicaltrials.gov) - Oct 27, 2014
P2, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Phase classification: P1/2 --> P2
- ||| Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Enrollment closed: PUMA-NER-4201: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2014
P2, N=104, Active, not recruiting, Sponsor: Puma Biotechnology, Inc.
Phase classification: P1/2 --> P2 Recruiting --> Active, not recruiting
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 17, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Nov 2014
- || Torisel (temsirolimus) / Pfizer
New P3 trial: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Oct 17, 2014
P3, N=253, Recruiting, Sponsor: National Cancer Institute (NCI)
- Oncaspar liquid (pegaspargase) / Servier, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 17, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Oct 10, 2014
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Jul 2014
- | Torisel (temsirolimus) / Pfizer
P4 data, Phase classification: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Oct 4, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2014 --> Jul 2014 Phase classification: P=N/A --> P4
- ||| Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Phase classification, Trial initiation date, Stroma, Metastases: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (clinicaltrials.gov) - Oct 4, 2014
P4, N=1600, Recruiting, Sponsor: Pfizer
Phase classification: P=N/A --> P4 Phase classification: P=N/A --> P4 | Initiation date: Feb 2008 --> Jan 2013
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - Sep 28, 2014
P1/2, N=63, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Phase classification: P=N/A --> P4 | Initiation date: Feb 2008 --> Jan 2013 Trial primary completion date: Dec 2014 --> Jun 2015
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (clinicaltrials.gov) - Sep 22, 2014
P1, N=278, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Sep 16, 2014
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jul 2013 --> Sep 2010
- | perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
New P2 trial: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (clinicaltrials.gov) - Sep 12, 2014
P2, N=17, Recruiting, Sponsor: Andrew Lassman
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial initiation date, Metastases: CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Sep 11, 2014
P1/2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2013 --> Sep 2010 Initiation date: Aug 2005 --> May 2005
- | Torisel (temsirolimus) / Pfizer
Phase classification: Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=120, Recruiting, Sponsor: Pfizer
Initiation date: Aug 2005 --> May 2005 Phase classification: P4 --> P=N/A
- | Torisel (temsirolimus) / Pfizer
P4 data, Phase classification: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=600, Recruiting, Sponsor: Pfizer
Phase classification: P4 --> P=N/A Phase classification: P4 --> P=N/A
- Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer
Enrollment change: Study of Axitinib and Temsirolimus in Solid Tumors (clinicaltrials.gov) - Sep 10, 2014
P1, N=13, Active, not recruiting, Sponsor: Emory University
Phase classification: P4 --> P=N/A N=50 --> 13
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 27, 2014
P1/2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=50 --> 13 Trial primary completion date: Jun 2014 --> Sep 2015
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment closed: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (clinicaltrials.gov) - Aug 21, 2014
P1/2, N=144, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- || Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Trial primary completion date: PUMA-NER-4201: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=104, Recruiting, Sponsor: Puma Biotechnology, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
New P1 trial, Metastases: TORERO: Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 15, 2014
P1, N=42, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- everolimus / Generic mfg.
Trial initiation date, Trial primary completion date: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Jul 30, 2014
P2, N=57, Not yet recruiting, Sponsor: Centre Leon Berard
Trial primary completion date: Jun 2014 --> Dec 2014 Initiation date: Jan 2014 --> Aug 2014 | Trial primary completion date: Jan 2016 --> Aug 2016
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 23, 2014
P1/2, N=12, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jan 2014 --> Aug 2014 | Trial primary completion date: Jan 2016 --> Aug 2016 Completed --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Enrollment change: Erlotinib and Temsirolimus for Solid Tumors (clinicaltrials.gov) - Jul 21, 2014
P1, N=46, Active, not recruiting, Sponsor: Washington University School of Medicine
Completed --> Active, not recruiting Recruiting --> Active, not recruiting | N=38 --> 46
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Jul 17, 2014
P2, N=378, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=38 --> 46 Active, not recruiting --> Completed | N=174 --> 378
- Torisel (temsirolimus) / Pfizer
Biomarker, Trial primary completion date, Metastases: Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=11, Active, not recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Active, not recruiting --> Completed | N=174 --> 378 Trial primary completion date: Apr 2014 --> Aug 2014
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial suspension, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=299, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2014 --> Aug 2014 Recruiting --> Suspended
- | Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion, Enrollment change, Trial primary completion date, Metastases: Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) (clinicaltrials.gov) - Jul 12, 2014
P1, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Active, not recruiting --> Completed | N=60 --> 23 | Trial primary completion date: May 2015 --> Jul 2014
- Torisel (temsirolimus) / Pfizer
Trial primary completion date, Pan tumor, Metastases: Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=44, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=60 --> 23 | Trial primary completion date: May 2015 --> Jul 2014 Trial primary completion date: Apr 2016 --> Jun 2014
- Torisel (temsirolimus) / Pfizer
Trial termination, Pan tumor, Metastases: Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=44, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Jun 2014 Active, not recruiting --> Terminated; Slow Accrual
- Torisel (temsirolimus) / Pfizer
Enrollment change, Trial termination, Trial primary completion date, Pan tumor, Metastases: Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=44, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Slow Accrual N=65 --> 44 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Jun 2014; Slow Accrual
- ||| Inlyta (axitinib) / Pfizer, Sutent (sunitinib) / Pfizer
HEOR, Real-world evidence, Real-world, Metastases: ADONIS: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=750, Not yet recruiting, Sponsor: Pfizer
- || Torisel (temsirolimus) / Pfizer
Trial primary completion date: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 1, 2014
P4, N=100, Recruiting, Sponsor: Pfizer
N=65 --> 44 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Jun 2014; Slow Accrual Trial primary completion date: May 2014 --> Aug 2015
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Jul 1, 2014
P2, N=74, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2014 --> Aug 2015 Suspended --> Recruiting
- | ganetespib (ADX-1612) / Aldeyra
Enrollment open, Combination therapy, Metastases: SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) (clinicaltrials.gov) - Jun 24, 2014
P1/2, N=38, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Suspended --> Recruiting Not yet recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus In Phase 0 (clinicaltrials.gov) - Jun 24, 2014
P0, N=15, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Jun 2014
- Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus In Phase 0 (clinicaltrials.gov) - Jun 24, 2014
P0, N=15, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2015 --> Jun 2014 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Trial primary completion date: Temsirolimus In Phase 0 (clinicaltrials.gov) - Jun 19, 2014
P0, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=18 --> 30 | Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jun 2014
- Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 17, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
N=18 --> 30 | Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jun 2014 N=39 --> 30
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=39 --> 30 N=92 --> 30
- Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 1, 2014
P1/2, N=12, Completed, Sponsor: Washington University School of Medicine
N=92 --> 30 Trial primary completion date: Mar 2012 --> Jan 2013
- Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 1, 2014
P1/2, N=12, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Mar 2012 --> Jan 2013 Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Enrollment closed: Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 22, 2014
P2, N=40, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Torisel (temsirolimus) / Pfizer
Trial initiation date: INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus (clinicaltrials.gov) - May 21, 2014
P=N/A, N=100, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Initiation date: May 2011 --> Jan 2011
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - May 21, 2014
P1/2, N=63, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Initiation date: May 2011 --> Jan 2011 Trial primary completion date: Apr 2014 --> Dec 2014
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Trial completion date, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - May 21, 2014
P1/2, N=63, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Apr 2014 --> Dec 2014 Trial completion date: Jan 2015 --> Sep 2015